A randomised phase II trial of Stereotactic Ablative Fractionated radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the lung (TROG 13.01 SAFRON II)
Shankar Siva, Tomas Kron, Mathias Bressel, Marion Haas, Tao Mai, Shalini Vinod, Giuseppe Sasso, Wenchang Wong, Hien Le, Thomas Eade, Nicholas Hardcastle, Brent Chesson, Daniel Pham, Morten Hoyer, Rebecca Montgomery, David Ball
BMC CANCER | BMC | Published : 2016
BACKGROUND: Stereotactic ablative body radiotherapy (SABR) is emerging as a non-invasive method for precision irradiation of lung tumours. However, the ideal dose/fractionation schedule is not yet known. The primary purpose of this study is to assess safety and efficacy profile of single and multi-fraction SABR in the context of pulmonary oligometastases. METHODS/DESIGN: The TROG 13.01/ALTG 13.001 clinical trial is a multicentre unblinded randomised phase II study. Eligible patients have up to three metastases to the lung from any non-haematological malignancy, each < 5 cm in size, non-central targets, and have all primary and extrathoracic disease controlled with local therapies. Patients a..View full abstract
Related Projects (1)
Awarded by Cancer Australia through the Priority-driven Collaborative Cancer Research Scheme
This study has been peer reviewed by the National Health and Medical Research Council (NHRMC) 2014 grant round and funded by Cancer Australia through the Priority-driven Collaborative Cancer Research Scheme APP1082399.